BDTX Q3 2021 Earnings — Black Diamond Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

BDTXBlack Diamond Therapeutics, Inc.

$125M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$35M

Net Income

-$35M

EPS (Diluted)

$-0.97

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$28M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$274M

Total Liabilities

$55M

Stockholders' Equity

$219M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$35M	-$18M	-91.4%
Net Income	-$35M	-$18M	-95.8%